Back to School: How biopharma can reboot drug development. Access exclusive analysis here

3Q approvals

3Q approvals

3Q approvals
Selected third quarter product approvals
Company Approval
Acambis (LSE:ACM) FDA approves ACAM2000 smallpox vaccine for use in subjects at high risk of exposure
Anesiva (ANSV) FDA approves Zingo needle-free injection of lidocaine powder to treat pain associated with venous access procedures in children ages 3-18
CSL (ASX:CSL) FDA approves Afluria influenza vaccine to prevent influenza types A and B in adults 18 years and older
Daiichi Sankyo FDA approves Azor fixed-dose combination of olmesartan and amlodipine to treat hypertension
Eli Lilly (LLY) FDA approves Evista raloxifene to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for breast cancer
GlaxoSmithKline (LSE:GSK; GSK) EC approves Cervarix vaccine to prevent precancerous lesions and cervival cancer caused by HPV types 16 and 18
Indevus (IDEV) FDA approves Sanctura XR, a once-daily formulation of Sanctura trospium, to treat overactive bladder (OAB)
LifeCycle

Read the full 1521 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE